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Type 2 diabetes is a metabolic disorder, characterized by hyperglycemia and glucose
intolerance. Natural products and its derived active compounds may be achievable
alternatives for the treatment of type 2 diabetes. In present study we investigated
the antidiabetic potential of Ficus microcarpa and isolated bioactive compounds i.e.,
Plectranthoic acid A (PA-A) and 3,4,5,7-Flavantetrol (FL). Anti-hyperglycemic potential
was evaluated via α-glucosidase, α-amylase and dipeptidyl peptidase 4 (DPP-4) assays.
5’AMP-activated kinase (AMPK) activation potential was assessed by using primary
hepatocytes. Distribution of PA-A in different parts of Ficus microcarpa was evaluated
by using rapid high-performance liquid chromatography (HPLC). Ethyl acetate fraction
(FME) exhibited significant inhibition of α-glucosidase, α-amylase, and DPP-4, therefore,
was selected for isolation of bioactive compounds. Among isolated compounds PA-A
was more potent and possessed pleotropic inhibitory activity with IC50 values of 39.5,
55.5, and 51.4 µM against α-glucosidase, α-amylase, and DPP-4, respectively. Our
results showed that PA-A is also a potent activator of AMPK which is a central
hub of metabolic regulation. Molecular docking studies confirmed the activity of PA-
A against α-glucosidase, α-amylase, and DPP-4. Rapid HPLC method revealed that
maximum concentration of PA-A is present in the stem (2.25 µg/mg dry weight) of
Ficus microcarpa. Both in vitro and in silico studies proposed that Ficus microcarpa
and its isolated compound PA-A could be an important natural source for alleviating the
symptoms of type 2 diabetes mellitus and we suggest that PA-A should be explored
further for its ultimate use for the treatment of type 2 diabetes.
Keywords: α-glucosidase, α-amylase, dipeptidyl peptidase 4, Ficus microcarpa, plectranthoic acid, AMPK
INTRODUCTION
Diabetes mellitus (DM) is multifactorial disorder of metabolism which is described by high
blood glucose levels known as hyperglycemia (Hu et al., 2013). Increase in blood glucose
level results in non-enzymatic glycosylation of numerous proteins and thus leads to chronic
complications of DM such as nephropathy, retinopathy and neuropathy (Lebovitz, 2001). Type 2
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diabetes mellitus (T2DM) leads to hyperglycemia, one of
the reasons is insufficient insulin production. Post-prandial
hyperglycemia is a key feature of T2DM and several therapies
focus on minimizing glycaemic excursions after a meal. For
example, if α-glucosidase and α-amylase are inhibited it will
reduce carbohydrate digestion in the lumen of the gut and,
thus, minimizing the amount of glucose available for absorption
thereby curbing post-prandial hyperglycemia (Bhandari et al.,
2008). Another enzyme that can be targeted to minimize post-
prandial hyperglycemia is dipeptidyl peptidase-4 (DPP-4) which
is serine protease. DPP-4 is famous for inhibition of two
incretin hormones. One of them is glucagon-like peptide 1 (GLP-
1) and other is glucose dependent-insulinotropic polypeptide
(GIP; Deacon et al., 1995). These incretin hormones are main
stimulators of post-prandial insulin excretion, thus play role in
the regulation of glucose levels after taking meal (Green et al.,
2004). Inhibition of DPP-4 will result in enhancement of activity
of incretin hormone. If DPP-4 is blocked GLP-1 and GIP will
not undergo degradation and their half-lives will be improved
and, consequently, will leads to the improvement of glucose
metabolism. The risk of hypoglycemia will also be reduced
(Lambeir et al., 2003).
Representatives of clinical antidiabetic drugs which inhibit
α-glucosidase /α-amylase include voglibose, miglitol, and
acarbose. Vildagliptin, sitagliptin, and saxagliptin are examples
of clinical DPP-4 inhibitors. Some adverse effects of these drugs,
like hypoglycemia, weight gain, fluid retention, congestive heart
failure, fractures, abdominal discomfort, increased intestinal gas,
and diarrhea, are reported (Etxeberria et al., 2012). Therefore,
there is a continuous interest in the discovery of naturally
occurring inhibitors of α-glucosidase, α-amylase and DPP-4,
which hopefully are non-toxic, lower cost and have less adverse
effects (Ren et al., 2011).
Reports show that the T2DM is also accompanied by decline in
5′ adenosine monophosphate-activated protein kinase (AMPK)
activity. The AMPK sense the metabolic status of the cell. If the
cell is in stress, the ratio of ADP: ATP and/or AMP: ATP will
be increased and AMPK will be activated. On activation, AMPK
stimulate catabolic pathways and switch off anabolic pathways.
AMPK on activation will also inhibit cell-cycle thus regulating
glucose levels, lipid and protein metabolism. AMPK activators
are reported to be valuable for the treatment and/or prevention
of T2DM (Ruderman and Prentki, 2004). Many compounds
activate AMPK such as phenformin, buformin, AICAR, and some
non-steroidal anti-inflammatory drugs (NSAIDs; Pollak, 2012).
Natural flavonoids, polyphenols, anthocyanin, and berberine are
also been presented to trigger AMPK (Hwang et al., 2007).
Although several AMPK stimulators have been identified, each
has its own limitations. AICAR has a short half-life and poor
bioavailability, phenformin and buformin induce lactic acidosis,
and metformin may increase the risk of death in non-obese
individuals. These are also recognized to have many targets and
toxic effects which are not dependent on AMPK. So, need of the
hour is to explore more AMPK activators for the treatment of
T2DM.
Various types of plants have been used for several centuries,
worldwide, not only as dietary supplements but also as traditional
treatment regimens for many diseases. Ficus microcarpa is one of
the Ficus species which is potentially valuable for its medicinal
usage, but is also a food ingredient (e.g., Okinawa noodles, a
traditional food in Japan). Anti-diabetic activity has previously
been reported for Ficus microcarpa extracts (Lakshmi et al.,
2010), but no studies have isolated or identified anti-diabetic
compounds from this plant. The aim of the present study was
to perform the bioactivity guided isolation on Ficus microcarpa
to identify potential compounds with inhibitory activity against
α-glucosidase, α-amylase, and DPP-4. We report for the first
time that Ficus microcarpa and Plectranthoic acid A (PA-
A) contains significant inhibitory activity against the above
mentioned enzymes and that PA-A (isolated for the first time
from this plant) could have potential for the treatment of T2DM.
Previously, we reported the anti-cancer potential of PA-A and
also showed that PA-A is non-toxic to normal cells (Akhtar
et al., 2016). Many reports show that the drugs with antidiabetic
potential increase AMPK activity. We already reported the
AMPK activation potential of PA-A using cancer cell lines but in
this study we evaluated the AMPK activation potential of PA-A
using hepatocytes. Furthermore, using high performance liquid
chromatography coupled with diode array detector (HPLC-
DAD), we have identified the specific parts of Ficus microcarpa
which are rich in PA-A.
MATERIALS AND METHODS
Plant Material
Fresh aerial parts of Ficus microcarpa were collected and
identified, as already reported (Akhtar et al., 2015). Voucher
specimen (33) accession number 128084 was deposited in
Herbarium of Medicinal Plants of Pakistan, Quaid-i-Azam
University, Islamabad 45320, Pakistan.
Extraction and Fractionation
Aerial parts of Ficus microcarpa (17 kg) were dried and extracted
using solvent system (Methanol/Chloroform; 1:1) following the
procedure reported by Jafri et al. (2017). We obtained almost
10 kg dry weight (DW) which was grounded to fine powder.
Scheme followed for preparation of crude extract (FMC) and
fractions, i.e., n-hexane fraction (FMN), ethyl acetate fraction
(FME) and aqueous fraction (FMA), is presented in Figure 1.
Isolation of Bioactive Compounds
For isolation of compounds with anti-hyperglycemic potential,
FME (200 g) was selected, due to better α-glucosidase, α-amylase
and DPP-4 inhibition activities. FME was further fractionated by
silica gel chromatography using n-hexane, ethyl acetate (EA) and
methanol (MeOH) step gradient system with gradually increasing
polarity, as reported by Jafri et al. (2017). Briefly, FME was
dissolved in appropriate solvents and were adsorbed on the silica
gel 60 (70–230 mesh, Merck, Germany) in the ratio of 1 g sample
on 1 g silica and dried in a fume hood. Then a glass column was
loaded with 1000 g silica gel 60 (230–400 mesh, Merck, Germany)
and the dried sample was loaded on the top. A protective layer
(2 cm) of silica gel was also added after loading the sample. The
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FIGURE 1 | Schematic representations of preparation of crude extract of
Ficus microcarpa (FMC) and its fractionations. FMN; n-Hexane fraction, FME;
Ethyl acetate fraction, FMA; Aqueous fraction.
column was eluted with gradient change in mobile phase. Each
fraction of 200 ml was collected and dried in rotary evaporator.
A total of 150 subfractions were obtained and those possessing
similar TLC profile, based on Rf values, were combined together
to obtain 6 major subfractions i.e., Ficus microcarpa ethyl acetate
fraction A (FMEA), Ficus microcarpa ethyl acetate fraction B
(FMEB), Ficus microcarpa ethyl acetate fraction C (FMEC), Ficus
microcarpa ethyl acetate fraction D (FMED), Ficus microcarpa
ethyl acetate fraction E (FMEE) and Ficus microcarpa ethyl
acetate fraction F (FMEF).
Flash column chromatography (silica gel 60; Merck) was
performed for further fractionation. Out of 6 subfractions, FMEB,
formed by combining fraction 10–20, was subjected to column
chromatography (silica gel 60, 5–40 µm), using mobile phase
from n-hexane to methanol in a gradient manner, and pure
compound FMEB-1 was isolated, as shown in Figure 2A. FMEE
(90 g combined fraction 55–70 from gravity column) was also
subjected to column chromatography and other pure compound
FMEE-1 was obtained, as shown in Figure 3A.
Structural Elucidation of Isolated
Compounds
A combination of mass spectrometry and nuclear magnetic
resonance spectroscopy (NMR) spectroscopy (Bruker AVANCE
(400 MHz NMR) was used to identify isolated compounds.
Both one dimensional and two dimensional NMRs were carried
out: 1H, 13C, 1H-13C heteronuclear single quantum correlation
(HSQC),1H-13C heteronuclear multiple bond correlation
(HMBC), 1H-1H correlation spectroscopy (COSY) and nuclear
overhauser effect spectroscopy (NOESY). Spectra of pure
compounds were processed by using Bruker 1D-NMR and 2D-
NMR software. The structures were confirmed by comparison of
spectroscopic data with reference data from available literature.
NMR data of PA-A is shown in Supplementary Figure 1.
Plectranthoic acid (PA-A): (20 S) 3α-hydroxy-18 α, 19 α
H-urs-12-en- 30β-oic acid, colorless needles, m.p. 260,” [α]
D25”+59◦ (c 0.1, MeOH), M+ at m/e 456.3628. IR: max cm-
1 3425 (-OH), 2930, 3200-2500 (br, -COOH), 1695, 1680, 1380,
1360. 1020. 820. H-NMR 1220 MHz). δ 0.68 (3H. s. C-24Me).
0.72 i3H, C-25 Me), 0.8 and 0.90 (9H;.s, C-23, c-26, c-27 Me’s),
0.96 (3H, s, C-28 Me), 1.05 (3H, C-29 Me), I.3Gl.80 (l8H, m),2.10
(IH, d, J = 5.2 Hz), 2.90 (IH, t, J = 16.9, 4 Hz), 4.37 (IH, m, W1/2
16.8 Hz), 5.12 (lH, s, br). MS: 456 (M+), 438 (M+-HzO), 41 I,
367,366,248 (100%), 208,207,204,203, 189. The NMR structure
revealed that the isolated compound is (PA-A), as shown in
Figure 2B. The data was consistent to the reported literature
(Razdan et al., 1982).
3,4,5,7- (FL): Description Computed from Structure
Canonical SMILES: C1C(C(OC2 = CC( = CC( = C21)O)O)
C3 = CC = C(C = C3)O)O. InChI: InChI = 1/C15H14O5/c16-
9-3-1-8(2-4-9)15-13(19)7-11-12(18)5-10(17)6-14(11)20-15/h1-
6,13,15-19H,7H2. The molecular structure of FL is shown in
Figure 3B. NMR data of FL is presented in Supplementary
Figure 2.
α-Glucosidase Inhibition Assay
α-Glucosidase inhibition activity of the fractions and pure
compounds (both PA-A and FL) was determined using the
method of Li et al. (2005), while few modifications were made,
according to system suitability. In this assay 4-nitrophenyl
β-D-glucopyranoside (pNPG) was used as a substrate and
enzymatic cleavage resulted in production of p-nitrophenol
(yellow color), monitored at 405 nm using microplate reader
(Biotec Elx-800, United States). The decrease in absorption
spectrum of reaction mixture indicated the inhibition of
α-glucosidase activity of the sample under test. Assays were
conducted in triplicate in 96-well microtitre plates. For crude
extract and fractions the final concentrations used were 200, 66.6,
22.2 and 7.4 µg/ml while for pure compounds the concentrations
used were 100, 50, 25, 12.5, 6.5 µM. Acarbose was used as positive
control while DMSO was used as negative control. Percentage of
inhibition was calculate by using following formula.
Inhibitory activity
= (OD control − OD test sample)/OD control × 100 (1)
IC50 was calculated by using table curve ASIN software (2D
v4) through linear regression analysis.
α-Amylase Inhibition Assay
Crude extract of Ficus microcarpa, its fractions and pure
compound (PA-A) were then subjected to evaluate their
α-amylase inhibition activity through the method documented
by Xiao et al. (2006). Reaction mixture (100 µl) was composed
of 30 µl PBS (50 mM), 10 µl enzyme (0.03 U/100 µl), 20 µl test
sample and 40 µl of soluble starch (2 g/L). Plates were placed at
50◦C for almost 30 min. To stop enzymatic reaction 20 µl of HCl
(1 M) was pipetted in all reaction mixtures and at the end iodine
reagent (100 µl; Iodine (5 mM) and potassium iodide (5 mM)),
was added. The color change and absorbance was recorded at
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FIGURE 2 | (A) Schematic demonstration of isolation and purification of Ficus microcarpa ethyl acetate fraction B (FMEB-1). FME; Ethyl acetate fraction of Ficus
microcarpa (B) Molecular structure of FMEB-1, identified as Plectranthoic acid A (PA-A).
540 nm. Inhibition percentage of the enzyme was measured by
using following formula:
%Relative enzyme activity
= (enzyme activity of test/
enzyme activity of control)∗100
α− amylase inhibition(%)
= (100−% relative enzyme activity). (2)
IC50 values were calculated by using table curve software
through linear regression analysis.
DPP-4 Inhibition Assay
DPP-4 inhibition activity was assessed by using fluorometric
technique, following the method documented by Saleem
et al., 2014. This method calculates the quantity of free
AMC (7-amino-4-methyl-coumarin). The AMC is released
from the Gly-Pro-AMC which is the substrate of DPP-4.
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FIGURE 3 | (A) Schematic demonstration of isolation and purification of Ficus microcarpa ethyl acetate fraction E (FMEE-1). FME; Ethyl acetate fraction of Ficus
microcarpa (B) Molecular structure of 3,4,5,7-Flavantetrol (FL).
Experiment was performed in triplicate. Fluorescence was
measured at Em 430 nm following excitation at Ex351 nm
using a Tecan safire desktop fluorometer (Reading, England,
United Kingdom). 50 mM HEPES buffer was used for
preparation of each sample, whose pH was 7.4. To each
well we added DPP-4 (20 µl 1 U/ml), test sample (20 µl)
and 1 mM AMC (30 µl). Plates were placed at 37◦C for 1 h
and then 3 mM acetic acid (100 µl) was pipetted to stop
the reaction. We used Berberine (13 mM), as a control for
each experiment, as already reported (Al-Masri et al., 2009).
IC50 for inhibition of DPP-4 was calculated for each
sample.
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FIGURE 4 | Percentage α-glucosidase inhibitory activity of crude extract, fractions and pure compounds from Ficus microcarpa (A). Crude extracts of Ficus
microcarpa and its fractions FMC; Crude extract of Ficus microcarpa, FMN; n-Hexane fraction, FME; Ethyl acetate fraction, FMA; Aqueous fraction. (B) PA-A and FL.
Values are presented as mean ± SD (∗P ≤ 0.05, ∗∗∗P ≤ 0.001).
FIGURE 5 | Percentage α-amylase inhibitory activity of crude extract, fractions and pure compound from Ficus microcarpa (A) crude extracts of Ficus microcarpa
and its fractions FMC; crude extract, FMN; n-hexane fraction, FME; ethyl acetate fraction and FMA; aqueous fraction. (B) PA-A. Values are presented as mean ± SD
(∗P ≤ 0.05, ∗∗P ≤ 0.01, and ∗∗∗P ≤ 0.001).
AMPK Activation Potential
To evaluate the AMPK activation potential of PA-A we performed
in vitro analysis. We used primary hepatocytes, derived from
C57BL/6 mice (Cell Biologics; Cat. C57-6224F). Hepatocytes
were kept in M199 (Corning), supplemented with FBS (fetal
bovine serum 10%) and glutagro (1% Corning). Hepatocytes
were then serum starved, overnight, and prior to procedure
in RPMI 1640 (United States Biological Life Sciences, R8999).
8 h prior to harvest, cells were treated with glucagon (2 µM),
or test sample (20 µM). Cells were rinsed with ice cold PBS,
twice, after harvest and were placed on ice until the extraction of
protein was carried out. Assay was conducted in triplicate with
three plates for each treatment. Protein from cells was hauled
out; quantified and western blot was performed to assess the
activation of AMPK after treatment with PA-A and compared it
with untreated control and the cells treated with glucagon.
Protein Extraction and Western Blot
Analysis
Extraction of proteins and western blot analysis was carried
out, as we already reported (Akhtar et al., 2016). Briefly, lysis
buffer was added to the harvested cells. The composition of
lysis buffer was 50 mM Tris–Hcl, 150 mM NaCl, 1 mM
ethylene glycol-bis (aminoethylether)-tetraacetic acid, 1 m
Methylene di amine tetra acetic acid, 20 mM NaF, 100 mM
Na3VO4, 0.5% NP-40, 1% Triton X-100, 1 mM phenyl methyl
sulfonyl fluoride, pH 7.4 with freshly added protease inhibitor
cocktail (Protease Inhibitor Cocktail Set III, Calbiochem, La
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FIGURE 6 | DPP-4 inhibition activity of crude extract, fractions and pure compound from Ficus microcarpa (A) Crude extract of Ficus microcarpa and its fractions.
FMC; Ficus microcarpa crude extract, FMN; n-hexane fraction, FME; ethyl acetate fraction and FMA; aqueous fraction. (B) PA-A. Values are presented as
mean ± SD. (∗P ≤ 0.05, ∗∗∗P ≤ 0.001).
FIGURE 7 | Induction of p-AMPK and p-ACC by PA-A. PA-A induced the
phorphrylation of AMPK in primary hepatocytes. To confirm equal loading
blots were reprobed with loading control i.e., GAPDH. p-AMPK; Phospho 5′
AMP-activated protein kinase, ACC; Acetyl-CoA carboxylase, C; Control
vehicle only, PA-A; PA-A, Glu; Glucagon.
Jolla, CA). Plates were placed on ice for 30 min. Cells
were scraped with the scraper and lysate was collected in
eppendorf tube and passed through needle of the syringe
to break up the cell aggregates. Lysate was cleared by
centrifugation at 14000 × g for 30 min at 4◦C and the
supernatant (whole-cell lysate) was used or immediately
stored at -80◦C. Concentration of protein in each lysate
was measured using Pierce BCA protein assay kit (Thermo
Scientific), as per manufacturer’s protocol. For western blotting
4–12% poly acrylamide gels were used to resolve 30 µg of
protein, transferred on to a nitrocellulose membrane, probed
with appropriate monoclonal primary antibodies and detected
by chemiluminescence autoradiography after incubation with
specific secondary antibodies.
Molecular Docking Studies
Molecular docking analysis was carried out using the software
molecular docking analysis (MOE) and MOE 2018 was used,
as reported by Ali et al. (2018). MOE is a licensed software
system1 designed by the Chemical Computing Group to support
cheminformatics, molecular docking, bioinformatics, virtual
screening, and structure-based-design and can be used to build
new applications based on scientific vector language (SVL). The
structures of ligands were prepared using builder tool of MOE
and then energy was minimized using force field MMFF94x
and these structures with minimized energy were saved in the
mdb file format. The 3-D structure of α-glucosidase, α-amylase
and dipeptidyl peptidase 4 (DPP-4) were obtained from the
protein data bank (PDB). The 3D structure of α-glucosidase [PDB
2ZE0] and α-amylase [PDB: ID1HNY] were obtained from the
PDB2 Selected 2ZE0 and 1HNY were fixed with the force field
MMFF94Xx to add up the hydrogen atoms, partial charges and
missing residues that can be used properly for the processes of
molecular docking.
Development of HPLC Quantification
Method
Instrumentation and Analytical Conditions
To select λmax in different mobile phases for HPLC analysis
100 µg/ml PA-A solutions were subjected to spectrophotometer
1https://www.chemcomp.com/MOE-Molecular_Operating_Environment.htm
2http://www.rcsb.org/pdb
TABLE 1 | Binding energies of docked compounds with α-glucosidase and
α-amylase.
Compound α-Glucosidase α-Amylase
IC50 Dock Score IC50 Dock Score
PA-A 39.5 −11.52 55.5 −5.63
FL 200 −9.13 NT –
Acarbose 12.5 −12.82 16.6 −9.72
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TABLE 2 | Analysis of the ligand interactions with localized amino acids residues at binding sites of α-glucosidase and α-amylase.
Compound α-Glucosidase α-Amylase
H-bonding AA H-bonding AA
PA-A 2.29, 2.43, 3.15 Arg197, Glu256, Ile143, 2.59, 2.66 Trp59, Glu233
FL 2.25 Glu256 NT -
Acarbose (2.95,2.52), 3.7, (2.78, 3.84),2.83 Asn258, Ile143, Asp199, Arg197 1.22, 1.99 Trp59, Glu233
scan by using PDA spectrophotometer (Aligent; United States).
For respective mobile phase different wavelengths were selected
from the spectrum. Chromatographic analysis was carried out
by using reverse phase high performance liquid chromatography,
coupled with diode array detector (RP-HPLC-DAD). Zorbex RX-
C8 analytical column (Agilent Tech; United States) was used for
chromatographic separation. RP-HPLC-DAD conditions were
optimized and mobile phase A, composed of MeOH:H2O/3:1,
and mobile phase B, composed of MeOH (100%), were used. The
mobile phase was freshly prepared, filtered and ultra-sonicated
for 5 min before use. Initially isocratic 50% B was used for 0–
15 min; then a gradient 15–18 min for 50% to 100% B; then again
isocratic 100% B was used for 18–23 min.
Standard Preparation
PA-A (10 mg) was dissolved in 5 ml of MeOH and sonicated
for 5 min. The solution was diluted to 1 mg/ml and then serial
dilutions were carried out to obtain 500, 250, 100, 50, 25, 10 and
2.5 µg/ml. Peak areas of eight concentrations (2.5–1000 µg/ml)
were used to plot calibration curve of PA-A. Chromatogram was
recorded thrice for each dilution.
Sample Preparation
Stem, root, adventitious root (ad. root), leaf and fruit of Ficus
microcarpa were collected. Each plant part was dried and almost
20 mg powder was extracted using 200 µl of MeOH/ Chloroform
(1:1).
Statistics
All experiments were performed in triplicate and mean values
were calculated. IC50 values were calculated using table curve
software. All statistical analysis was carried out with GraphPad
prism (San Diego, CA).
RESULTS
α-Glucosidase Inhibitory Activities
In current investigation, crude extract of Ficus microcarpa
(methanol:chloroform/1:1); its fractions i.e., n-hexane (FMN),
ethyl acetate (FME), aqueous (FMA) and the isolated compounds
were subjected to evaluate α-glucosidase inhibition potential.
Enzyme inhibition was calculated as percentage of inhibition as
shown in Figure 4. Inhibitory activity of FMC and fractions
varied noticeably. The α-glucosidase inhibitory activity of FMC,
FMN, FME, and FMA was 62 ± 3%, 51.2 ± 1.8%, 68.6 ± 3.1%,
and 60 ± 2.5% at 200 µg/ml, 49 ± 1.8%, 40.2 ± 1.5%,
51 ± 1.6%, and 40 ± 1.7% at 66.6 µg/ml, 21 ± 1.5%,
14 ± 2.2%, 28 ± 1.2%, and 20 ± 1.1% at 22.2 µg/ml, and
10 ± 0.5%, 5 ± 0.6%, 5 ± 0.8%, and 8 ± 0.4% at 7.4 µg/ml,
respectively. The observed α-glucosidase inhibitory activity of
crude extract and fractions in descending order was; ethyl acetate
fraction (FME) > crude extract (FMC) > aqueous fraction
(FMA) > n-hexane fraction (FMN), as shown in Figure 4A.
All samples exhibited concentration dependent inhibition of
α-glucosidase. IC50 values of FMC, FMN, FME, and FMA were
80.3 ± 5.4 µg/ml, 175.04 ± 6.5 µg/ml, 61.2 ± 5.5 µg/ml, and
135.9 ± 6.8 µg/ml, respectively. Among compounds (PA-A)
showed better inhibitory activity as compared to 3,4,5,7- (FL), as
shown in Figure 4B. IC50 values of PA-A and FL were found to
be 39.5± 3.5 µM and 200± 6.8 µM, respectively. The IC50 value
of acarbose was 12.5± 2.1 µM, used as positive control.
α-Amylase Inhibitory Activities
α-Amylase inhibitory activity of crude extract, fractions (FMN,
FME, and FMA) and isolated compound (PA-A) was evaluated
at different concentrations, as shown in Figure 5A. First
crude extracts and fractions were subjected to α-amylase
inhibition assay. FME showed better inhibitory activity, with
percentage inhibition 62 ± 2.9%, 43 ± 2.1%, 25 ± 1.1%,
18 ± 0.9% at 200, 66.6, 22.2, and 7.4 µg/ml, respectively,
(Figure 5A), as compared to other fractions. Inhibitory activity
of crude extract and fractions in the descending order was
FMC > FME > FMA > FMN, with IC50 values 77 ± 2.5 µg/ml,
85.2 ± 5.5 µg/ml, 186 ± 5.5 µg/ml, and > 200 µg/ml,
respectively. Due to potent inhibition activity, FME was selected
for isolation of bioactive compounds with anti-hyperglycemic
potential. PA-A was subjected to α-amylase inhibitory activity
and results showed that PA-A exhibited significant α-amylase
inhibition activity in a concentration dependent manner. The
percentage of inhibition was 60 ± 2.5%, 55 ± 2.1%, 38 ± 1.8%,
12 ± 1.1%, and 8 ± 0.5% at 100, 50, 25, 12.5, and 6.25 µM,
respectively, with IC50 value 55.5 ± 2.5 µM (Figure 5B). FL
was not included in this study because of its low efficacy in
inhibiting α-glucosidase. Acarbose was used as positive control
for α-amylase inhibition with IC50 value 16.6± 3.5 µM.
Dipeptidyl Peptidase-4 Inhibition
We assessed DPP-4 inhibition activity of crude extract and
fractions of Ficus microcarpa. Results showed that DPP-4
inhibition potential of crude extract (FMC) and fractions varied
significantly might be due to difference in the composition
of compounds within each sample. The inhibitory activity of
crude extract was 61.5 ± 1.2%, 65.6 ± 1.8%, 76.1 ± 2.2%,
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FIGURE 8 | Molecular docking PA-A, FL and Acarbose (A). PA docked with α-glucosidase (B). Docked FL (C). Acarbose in the active site (D). Docked poses of PA
and Acarbose in active site of α-amylase.
and 73.1 ± 2.3% at 200 µg/ml as shown in Figure 6A.
Among fractions, FME showed maximum inhibitory activity with
percentage of inhibition 76.1 ± 2.2%, 65 ± 1.5%, 52 ± 0.9%,
and 41 ± 1.8% at 200, 66.6, 22.2, and 7.4 µg/ml, respectively.
Calculated IC50 values of FMC and fractions in descending order
were FME (20.5 ± 2.3 µg/ml) > FMA (62 ± 1.3 µg/ml) > FMC
(95.2 ± 2.1 µg/ml) > FMN (109.5 ± 5.6 µg/ml). PA-A showed
significant DPP-4 inhibition activity with percentage of inhibition
65 ± 2.6%, 55 ± 2.1%, 48 ± 2%, 25 ± 2.9%, and 15 ± 2% at
100, 50, 25, 12.5, and 6.25 µM, respectively, and IC50 value of
PA-A was 51.4 ± 2.0 µM (Figure 6B). Berberine was used as
the positive control for DPP-4 inhibition and with IC50 value
27.4± 2.2 µM.
AMPK Activation Potential
Most of the drugs with antidiabetic potential, such as metformin,
activate AMPK. As we found that PA-A had anti-hyperglycemic
potential we further assessed the AMPK activation potential
of PA-A, using primary hepatocytes. For this purpose we
treated the cells with PA-A (20 µM). Results showed that PA-
A activates AMPK by phosphorylation AMPK at Th172, as
shown in Figure 7. Glucagon was used as a control because
it increase inhibitory phosphorylation of AMPK (Ser173) and
reduce active phosphorylation of AMPK (Thr172) due to PKA-
mediated inhibition of AMPK (Aw et al., 2014). We observed that
there was no AMPK activation in cells treated with glucagon and
vehicle control, as expected. Further, we evaluated the effect of
PA-A mediated AMPK activation on phosphorylation of acetyl-
CoA carboxylase (ACC). Results from the western blot showed
that AMPK was activated by PA-A which in turn phosphorylated
ACC to p-ACC at S79 site (Figure 7). The phosphorylation was
not observed in glucagon and vehicle control.
Molecular Docking
Molecular docking studies of PA-A, FL and acarbose were
performed in the active site of α-glucosidase [PDB 2ZE0]
and α-amylase [PDB ID 1HNY]. Binding energies of these
compounds are given in Table 1, 2. Docking score of PA-A
with α-glucosidase was -11.5 while with α-amylase was -5.63.
FL was also docked with α-glucosidase and recorded binding
energy was -9.13. Docking poses and binding patterns of the
pure compounds and acarbose, used as standard, are shown in
Figure 8.
Quantification of PA-A in Different Parts
of Ficus microcarpa
Quantitative analysis of PA-A in different parts of Ficus
microcarpa i.e., root, stem, leaf and adventitious roots was carried
out by using reverse phase HPLC. Chromatographic profile was
compared with the retention time and absorption spectrum of
reference standard. Calibration curve of the standard compound
was constructed and its statistical analysis is shown in Table 3.
Representative chromatograms of PA-A in stem and leaf are
shown in Supplementary Figure 3 while of fruit, adv. root
and root are shown in Supplementary Figure 4. The results
revealed that maximum amount of PA-A was present in stem
i.e., 2.2 ± 0.2 µg/mg dry weight (DW), while in leaf and fruit
1.529± 0.08 µg/mg DW and 1.06± 0.1 µg/mg DW quantity was
detected, respectively. Moreover, the results revealed that PA-A
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TABLE 3 | Statistical analysis of calibration curve of Plectranthoic acid.
Studied Parameters Results
Beer’s law limit 2.50–1000
λmax 210 nm
Regression Equation y = 1.3697 x − 13.10
Correlation coefficient 0.9997
Detection limit 2.5 µg/ml
Quantification limit 2.5 µg/ml
was not found in roots and adventitious roots of Ficusmicrocarpa.
Results are presented in Figure 9.
DISCUSSION
From previous studies in which we screened 61 medicinal plants
(Akhtar et al., 2015), we concluded that Ficus microcarpa is
one of the most promising plants with therapeutic potential for
further studies due to high total phenolic and total flavonoid
content. As former studies using albino wistar rats reported that
Ficus microcarpa possess anti-diabetic activity (Lakshmi et al.,
2010), we hypothesized that the isolated compounds might have
such properties. Type 2 diabetes (T2DM) is the 7th leading
cause contributing to death of many individuals in United States
and current therapies leave much room for improvement. Most
of the suffered individuals require multiple prescriptions to
reduce glucose levels of blood (Tiwari and Rao, 2002). In
proposed study, we assessed the anti-hyperglycemic potential
of Ficus microcarpa and isolated pure compounds, evaluated
their potential use against T2DM. We collected aerial parts of
Ficus microcarpa and prepared crude extract through maceration
process using M/C (1:1). The FMC was then subdivided into
FIGURE 9 | High-performance liquid chromatography (HPLC) profile of PA-A
in different parts of Ficus microcarpa. Quantification of PA in different parts of
Ficus microcarpa. Adv root, adventitious root. DW, Dry weight. Significant
differences between the amount of PA-A were observed (p < 0.001) in each
part of Ficus microcarpa.
different fractions by solvent-solvent extraction i.e., non- polar
n-hexane fraction (FMN), moderately polar ethyl acetate fraction
(FME) and highly polar aqueous fraction (FMA). Crude extract
and fractions were then subjected to α-glucosidase, α-amylase
and DPP4 inhibition assays. Previous studies showed that
inhibition of just α-glucosidase significantly reduces glucose
levels and clinically it is used extensively for treatment of T2DM
(Etxeberria et al., 2012). Current research revealed that Ficus
microcarpa is a valuable source of natural compounds which
can inhibit α-glucosidase, α-amylase and DPP-4, consequently,
can be used for T2DM treatment. The results correlate with the
study of Lakshmi et al. (2010) whose work suggests that Ficus
microcarpa might be new clinical choice in (DM) treatment.
Our results showed that FME had better α-glucosidase
and α-amylase inhibition as compared to other fractions.
Interestingly, other fractions also showed good percentage of
inhibition for above mentioned enzymes. This suggests that
Ficus microcarpa is a rich source of bioactive compounds of
diverse polarity having anti-hyperglycemic potential. Usually
phenolic compounds possess strong inhibitory activity possibly
due to the presence of the glycosidic groups on phenolic
scaffolds (Apostolidis et al., 2007). Recently, the DPP-4 enzyme
is going to be famous and has emerged as important target
of antidiabetic drugs. Pharmaceutical industries have made
efforts which resulted in the development and improvement
of DPP-4 inhibitors; having better safety and efficacy profiles.
Unfortunately, there are few studies about the presence of
DPP-4 inhibitors in medicinal plants (Parmar et al., 2012). In
presented work, we evaluated the DPP-4 inhibition potential
of Ficus microcarpa and it is worthy to mention that Ficus
microcarpa possessed significant ability to inhibit DPP-4.
Maximum inhibition percentage was exhibited by FME with IC50
20.5± 2.3 µg/ml.
Next, we designed experiments to isolate compounds with
anti-hyperglycemic potential Based on the results of the
assays; FME was selected for isolation of bioactive compounds.
Bioactivity guided isolation yielded 2 pure compounds, 1). (PA-
A); 2). 3,4,5,7- (FL). PA-A is a pentacyclic triterpenoid. Triterpene
is a diverse class of natural compounds and several diverse
structures of these are reported until now. Pentacyclic triterpenes
comprised of 30-carbon skeleton with five or four six-membered
rings and a five-membered ring. PA-A was first isolated by
Razdan and his colleagues from Plectranthus rugosus in 1982.
We have isolated this compound from Ficus microcarpa for
the first time. Other isolated compound was FL, which is a
flavonoid and literature showed that flavonoids have important
effects on cancer chemoprevention and chemotherapy (Chahar
et al., 2011). FL/Afzelechin is a flavan-3-ol, reported to be
isolated from rhizomes of Bergenia ligulata (Saijyo et al., 2008).
Anti-hyperglycemic activities of flavonoids have been previously
reported (Yan et al., 2014). These are also well known for DPP-4
inhibition potential (Parmar et al., 2012).
Among two compounds PA-A exhibited promising inhibitory
activity against α-glucosidase and α-amylase at various
concentrations as compared to FL. Hydroxyl (OH) groups
are postulated to interact with yeast α-glucosidase active site
amino acids by hydrogen bonds, thus inhibiting the catalysis
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of the substrate (Xu, 2010). Considering the structure of PA-A,
it can be deduced that its OH group may interact with the
enzyme active site and thus, is responsible for the inhibition
of the enzyme activity. PA-A also showed DPP-4 inhibition,
with IC50 51.4 ± 2.0 µM, supporting its promising potential
as anti-hyperglycemic agent. Many triterpenoids are already
reported to have antidiabetic properties such as oleanolic acid
and ursolic acid (Ali et al., 2006), but this is the first instance
that the triterpenoid, i.e., PA-A, has been proposed to have
anti-diabetic effects.
Recently, AMPK has emerged as an effective target for T2DM
treatment, because it is the major regulator of energy within the
cell. It is stimulated in calorie restriction and physical activities,
thus increasing insulin sensitivity of tissues and enhancing
glucose uptake. Pharmacological stimulation of AMPK provokes
many benefits like improvement of insulin sensitivity and glucose
homeostasis, making it an attractive target for T2DM and
metabolic syndrome (Ruderman and Prentki, 2004). Although
the drugs that activate AMPK are available i.e., Metformin, TZDs,
but their potential for direct activation of AMPK is debatable, as
many off-targets effects of these drugs are reported (Ben Sahra
et al., 2011). There is a need of new AMPK activators with no
side effects. In this study we evaluated the AMPK activation
potential of PA-A using primary hepatocytes and found that PA-
A is a potent activator of AMPK, which we already evaluated
using cancer cells (Akhtar et al., 2016). We also presented that
PA-A is non-toxic to normal cells (Akhtar et al., 2016). AMPK is
reported as a regulator of ACC (acetyl-CoA). It phosphorylates
ACC at serine residues including Ser79 (Park et al., 2002), thus
playing role in regulation of fatty acid synthesis and degradation.
To confirm activation of AMPK by PA-A, we further assessed
the phosphorylation of ACC at Ser79. Results showed that PA-A
treatment resulted in the phosphorylation of ACC which is the
substrate of AMPK, thus confirms the role of PA-A as activator of
AMPK.
In silico studies showed a good correlation with experimental
results. Observed high activity of PA-A was might be due to
its strong binding interactions with target. PA-A has strong
hydrogen binding with Arg197 at distance of 2.29, Glu 256 at
distance of 2.43 and Ile143 at distance of 3.15 (Figure 8A). Low
activity of FL against α-glucosidase was might be due to its fewer
efficacies with target as it has one hydrogen binding with Glu 256,
as shown in Figure 8B. Acarbose has strong binding interaction
with both α-glucosidase and α-amylase as shown in Table 2 and
Figure 9C. Similarly, activity of PA-A against α-amylase was
confirmed by its hydrophilic interactions with Trp 59 and Glu 233
as shown in Figure 8D. PA-A showed significant interactions and
good binding scores with both targets (Figure 8), which increase
its value as a potential dual inhibitor.
Next, we quantified PA-A in different parts of Ficus
microcarpa. For this purpose, different parts of Ficus microcarpa
i.e., root, adventitious root, stem, leaf and fruit were extracted by
using different solvents among which n-hexane: ethyl acetate /2:1
was found to be most suitable with 98% recovery. This displayed
greater selectivity for the analyte while reduced polar interfering
compounds. Results revealed that maximum concentration of
PA-A was perceived in stem while fewer in leaf and fruit.
Moreover, HPLC results showed that PA-A is not found in roots
and adventitious roots of Ficus microcarpa, so we recommend
stem for the isolation of this potent compound.
In this study we proposed that PA-A is a potent compound
with anti-hyperglycemic potential. In-vivo studies using animal
models or diabetic patients, for detailed antidiabetic effects along
with identification of potential targets, are recommended and are
part of our future studies.
CONCLUSION
Taken together study revealed that Ficus microcarpa is a valuable
source of compounds with anti-hyperglycemic potential. Our
studies showed that PA-A is a bioactive compound, the potential
anti-hyperglycemic activities of which have hitherto remained
unexplored. (PA-A) has potential to inhibit α-glucosidase,
α-amylase and DPP-4 and is a potent activator of AMPK, thus
can be used for the development of nutraceuticals and functional
foods for T2DM. Evaluation of potent activities and identification
of potential targets of PA-A in other clinical models, both in vitro
and in vivo, is mandatory for its translation as an effective agent
against T2DM.
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FIGURE S1 | NMR spectrum of Plectranthoic acid A (PA-A): (A). 1H NMR
spectrum of PA-A (B). 13C NMR spectrum of PA-A (C). HMBC spectrum of PA-A
(D). HSQC spectrum of PA-A.(E). NOESY spectrum of PA-A (F). COSY spectrum
of PA-A.
FIGURE S2 | NMR spectrum of 3,4,5,7-Flavantetrol/Afzelechin (FL) (A). 1H NMR
spectrum of FL (B). 13C NMR spectrum of FL (C). HMBC of FL (D). HSQC of FL
(E). NOESY of FL (F). COSY of FL.
FIGURE S3 | Representative HPLC chromatograms of (A). Standard (B). Stem
(C). Leaf.
FIGURE S4 | Representative HPLC chromatograms of (A). Fruit (B).
Advantageous root (C). Root.
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